Viewing Company
Company Name:
ALTAMIRA THERAPEUTICS LTD.
CIK:
1601936
Phone:
None
Fiscal Year End:
None
Entity Type:
SIC:
-
Category Type:
Entity Name:
None
First Filing Date:
2018-03-22
Last Filing Date:
2025-04-30
SEC Filings
| Start | End | Frame | Filed | ACCN | Value | View |
|---|---|---|---|---|---|---|
| 2023-12-31 | CY2023Q4I | 2024-07-01 | 0001213900-24-057548 | $ 1,477,785 | View | |
| 2022-10-10 | 2022-06-30 | CY2022Q2I | 2023-08-21 | 0001213900-23-069125 | $ 182,167 | View |
| 2023-01-01 | 2023-06-30 | CY2023Q1I | 2023-09-12 | 0001213900-23-075871 | $ 37,018 | View |
| 2024-01-01 | 2023-05-01 | CY2023Q1I | 2024-09-24 | 0001213900-24-081199 | $ 6 | View |
| 2019-01-01 | 2019-06-30 | CY2019Q2I | 2019-08-15 | 0001213900-19-015943 | $ -3,604,301 | View |
| 2017-01-01 | 2017-12-31 | CY2015 | 2018-03-22 | 0001601936-18-000007 | $ 43,741,870 | View |
| 2018-01-01 | 2018-12-31 | CY2016 | 2019-03-14 | 0001601936-19-000008 | $ 15,900,865 | View |
| 2021-01-01 | 2021-12-31 | CY2021 | 2022-04-12 | 0001213900-22-019292 | $ 470,958 | View |
| 2023-05-01 | 2023-05-12 | CY2023Q1I | 2024-04-22 | 0001213900-24-034940 | $ 0 | View |
| 2023-01-01 | 2024-12-31 | CY2024Q4I | 2025-04-30 | 0001213900-25-037199 | $ 361,053 | View |
| 2020-01-01 | 2020-06-30 | CY2020Q2I | 2020-09-17 | 0001213900-20-027077 | $ -2,658,501 | View |
| 2019-01-01 | 2019-12-31 | CY2017 | 2020-04-16 | 0001213900-20-009292 | $ 3,325,281 | View |
| 2021-01-01 | 2020-12-31 | CY2020Q4I | 2021-09-08 | 0001213900-21-046965 | $ 523,920 | View |
| 2020-01-01 | 2020-12-31 | CY2020Q4I | 2021-03-31 | 0001213900-21-018959 | $ 16,769,890 | View |
| 2022-10-10 | 2021-06-30 | CY2021Q2I | 2022-11-30 | 0001213900-22-076042 | $ 87,931 | View |
| 2022-01-01 | 2022-12-31 | CY2022 | 2023-05-16 | 0001213900-23-040152 | $ 12,397,148 | View |
SEC Facts By Type
| Type | Name | Description | View |
|---|---|---|---|
| ifrs-full | 2740299 | None | View |
| us-gaap | Conversion of Stock, Shares Issued | "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. ""Part noncash"" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." | View |
| us-gaap | Number of Operating Segments | Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues. | View |
| dei | Entity Common Stock, Shares Outstanding | Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. | View |
| us-gaap | Debt Conversion, Original Debt, Amount | "The amount of the original debt being converted in a noncash (or part noncash) transaction. ""Part noncash"" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." | View |
| us-gaap | Debt Instrument, Convertible, Conversion Price | The price per share of the conversion feature embedded in the debt instrument. | View |
| us-gaap | General and Administrative Expense | The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. | View |
| us-gaap | Liabilities | Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. | View |
| us-gaap | Net Income (Loss) Attributable to Parent | The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. | View |
| us-gaap | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. | View |
| us-gaap | Research and Development Expense | The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. | View |
| us-gaap | Short-term Debt | Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer. | View |
| us-gaap | Stockholders' Equity Attributable to Parent | Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. | View |
| us-gaap | Common Stock, Shares, Issued | Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. | View |
| us-gaap | Asset Impairment Charges | Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill. | View |
Chart of Accounts => Accounts
| Name | View |
|---|---|
| Conversion of Stock, Shares Issued | View |
| Debt Conversion, Original Debt, Amount | View |
| Debt Instrument, Convertible, Conversion Price | View |
| General and Administrative Expense | View |
| Liabilities | View |
| Net Income (Loss) Attributable to Parent | View |
| Number of Operating Segments | View |
| Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | View |
| Research and Development Expense | View |
| Short-term Debt | View |
| Stockholders' Equity Attributable to Parent | View |
| Common Stock, Shares, Issued | View |
| Asset Impairment Charges | View |